Antitumor agent-60

Modify Date: 2024-01-04 09:48:50

Antitumor agent-60 structure	Common Name	Antitumor agent-60
	CAS Number	865784-65-2	Molecular Weight	508.54
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₄H₂₈O₁₀S	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Antitumor agent-60

Antitumor agent-60 (compound 20) is a potent antitumor agent, targeting RAS-RAF signaling pathway and binding to CRAF with a Kd value of 3.93 μM. Antitumor agent-60 induces apoptosis by blocking cell cycle at G2/M phase. Antitumor agent-60 enhances the level of p53 and ROS. Antitumor agent-60 causes oval and irregular nucleus in cancer cells. Antitumor agent-60 can suppress the growth of tumor to some extent in A549 xenograft model[1].

Name	Antitumor agent-60

Description	Antitumor agent-60 (compound 20) is a potent antitumor agent, targeting RAS-RAF signaling pathway and binding to CRAF with a Kd value of 3.93 μM. Antitumor agent-60 induces apoptosis by blocking cell cycle at G2/M phase. Antitumor agent-60 enhances the level of p53 and ROS. Antitumor agent-60 causes oval and irregular nucleus in cancer cells. Antitumor agent-60 can suppress the growth of tumor to some extent in A549 xenograft model[1].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Signaling Pathways >> Apoptosis >> MDM-2/p53 Signaling Pathways >> Protein Tyrosine Kinase/RTK >> ROS Signaling Pathways >> MAPK/ERK Pathway >> Raf Signaling Pathways >> GPCR/G Protein >> Ras
Target	IC50: 12 nM in A549, 19 nM in OVCaR-3, 29 nM in SGC-7901, 22 nM in HCT-116[1] Kd: 721.3 nM (CRAF RBD)[1]
References	[1]. Liu Z, et al. Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance. Eur J Med Chem. 2020;194:112269.

Molecular Formula	C₂₄H₂₈O₁₀S
Molecular Weight	508.54

Antitumor agent-60

Use of Antitumor agent-60

Names

Antitumor agent-60 Biological Activity

Chemical & Physical Properties